ZA9810710B - Sustained release formulations comprising alpha-glucosidase-inhibitors - Google Patents

Sustained release formulations comprising alpha-glucosidase-inhibitors

Info

Publication number
ZA9810710B
ZA9810710B ZA9810710A ZA9810710A ZA9810710B ZA 9810710 B ZA9810710 B ZA 9810710B ZA 9810710 A ZA9810710 A ZA 9810710A ZA 9810710 A ZA9810710 A ZA 9810710A ZA 9810710 B ZA9810710 B ZA 9810710B
Authority
ZA
South Africa
Prior art keywords
glucosidase
inhibitors
alpha
sustained release
release formulations
Prior art date
Application number
ZA9810710A
Inventor
David Goldman
John Amatruda
Carola Portner
Erich Brendel
Patrick Bosche
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA9810710B publication Critical patent/ZA9810710B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA9810710A 1997-11-25 1998-11-24 Sustained release formulations comprising alpha-glucosidase-inhibitors ZA9810710B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6669897P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
ZA9810710B true ZA9810710B (en) 1999-06-14

Family

ID=22071124

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810710A ZA9810710B (en) 1997-11-25 1998-11-24 Sustained release formulations comprising alpha-glucosidase-inhibitors

Country Status (5)

Country Link
JP (1) JP2001523704A (en)
AR (1) AR017664A1 (en)
AU (1) AU1234399A (en)
WO (1) WO1999026606A2 (en)
ZA (1) ZA9810710B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL186223A0 (en) * 2000-05-24 2008-01-20 Pfizer Treatment of rumen acidosis with ??-amylase inhibitors
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
CA2494179C (en) 2002-08-08 2012-04-24 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US7375113B2 (en) 2004-03-04 2008-05-20 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
CN102631332A (en) * 2012-04-28 2012-08-15 邹立兴 Voglibose tablet and preparation method thereof
CN104013590A (en) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 Acarbose-containing medicinal composition and preparation method thereof
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
CN110898025A (en) * 2019-12-12 2020-03-24 湖北欣泽霏药业有限公司 Acarbose sustained-release preparation and preparation method thereof
CN111265489A (en) * 2020-03-10 2020-06-12 乐普制药科技有限公司 Divisible acarbose pellet sustained-release tablet

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (en) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen NEW MEDICINE PREPARATIONS FOR GLYCOSIDE HYDROLASE INHIBITORS
DK97986A (en) * 1985-03-08 1986-09-09 Takeda Chemical Industries Ltd Means for inhibiting the digestion of saccharide
ATE86853T1 (en) * 1988-08-22 1993-04-15 Takeda Chemical Industries Ltd ALPHA-GLUCOSIDASE INHIBITOR TO PROMOTE CALCIUM ABSORPTION.
TW272942B (en) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
AR017664A1 (en) 2001-09-12
WO1999026606A3 (en) 1999-08-12
JP2001523704A (en) 2001-11-27
AU1234399A (en) 1999-06-15
WO1999026606A2 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
EP1043030A4 (en) Sustained release medicinal compositions
GB9715751D0 (en) Formulations
PL343096A1 (en) Sustained release preparations
IL180864A0 (en) Sustained release ranolazine formulations
EG24198A (en) Extended release formulation
EP1049486A4 (en) Glp-1 formulations
SG71879A1 (en) Controlled release compositions
HK1040037A1 (en) Microcapsule formulations
GB2323531B (en) Therapeutic formulations
IL135457A0 (en) Extended release formulation
SG71789A1 (en) Controlled release compositions
GB2310860B (en) Stable release agents
PL346414A1 (en) Microcapsule formulations
ZA975703B (en) Sustained release sufentanil compositions
ZA9810710B (en) Sustained release formulations comprising alpha-glucosidase-inhibitors
GB2322867B (en) Release agent
GB9915929D0 (en) Novel release latch-c-i-p
SI1009387T1 (en) Stabilized sustained release tramadol formulations
GB9704521D0 (en) Formulations
GB9703101D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9703099D0 (en) Formulations
GB9816563D0 (en) Controlled release formulations
GB9727229D0 (en) Sustained release inhalation compositions
GB9720228D0 (en) Parasiticidal formulations